Contineum Therapeutics In... (CTNM)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need.
Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).
The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist.
Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023.
The company was incorporated in 2009 and is headquartered in San Diego, California.
Country | United States |
IPO Date | n/a |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 31 |
CEO | Carmine N. Stengone MBA, MS |
Contact Details
Address: 10578 Science Center Drive San Diego, California United States | |
Website | https://www.contineum-tx.com |
Stock Details
Ticker Symbol | CTNM |
Exchange | NASDAQ |
Fiscal Year | n/a |
Reporting Currency | USD |
CIK Code | 0001855175 |
CUSIP Number | n/a |
ISIN Number | US21217B1008 |
Employer ID | 27-1467257 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Carmine N. Stengone MBA, MS | President, Chief Executive Officer, Secretary & Director |
Peter T. Slover CPA | Chief Financial Officer |
Austin Chen Ph.D. | Senior Vice President & Head of Research |
Dr. Daniel S. Lorrain Ph.D. | Chief Science Officer |
Dr. Stephen L. Huhn F.A.A.P, F.A.C.S., M.D. | Chief Medical Officer & Senior Vice President of Clinical Development |
John Healy | General Counsel & Corporate Secretary |
Michael Mayberry | Senior Director & Corporate Controller |
Morgan Paulsen | Senior Manager of Accounting |
Steve E. Kunszabo | Senior Director of Investor Relations & Corporate Communications |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 27, 2024 | 4 | Filing |
Nov 20, 2024 | 4 | Filing |
Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Nov 06, 2024 | 10-Q | Quarterly Report |
Nov 06, 2024 | 8-K | Current Report |
Oct 31, 2024 | SCHEDULE 13G | Filing |
Aug 14, 2024 | 4 | Filing |
Aug 14, 2024 | 10-Q | Quarterly Report |
Aug 14, 2024 | 8-K/A | [Amend] Current Report |
Aug 13, 2024 | 8-K | Current Report |